At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
Intravitreal Aflibercept Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Optical Coherence Tomography Guided Treat and Extend Therapy for Neovascular Age Related Macular Degeneration Using Aflibercept (the ATLAS Study)
In Brief
A clinical study evaluating Intravitreal Aflibercept Injection for Age-Related Macular Degeneration and Macular Degeneration. Completed, enrolled 40 participants across 3 sites.
Detailed Summary
To evaluate the visual outcome and number of injections required during an optical coherence tomography (OCT)-guided treat and extend regimen with intravitreal aflibercept for treatment of subfoveal neovascular age-related macular degeneration (NVAMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartFeb 2013
Primary CompletionMar 2016
TodayJul 2026
First PostedJan 23, 2013
Enrollment StartFeb 1, 2013
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 13.4 years ago
Interventions
Intravitreal Aflibercept Injectiondrug
Increased or decreased time between visits